
|Articles|September 22, 2022
New Phesi Analysis of Alzheimer’s Patients Highlights Need for Preventative Approach that Includes Younger Participants
Advertisement
Phesi identified 117,463 patients who participated in disease modifying trials; representing a significant portion of the patient population. The Phesi analysis reveals the decline that occurs in Alzheimer’s patients over a single 12-month period, with the average 72-year-old suffering from Alzheimer’s losing 18% of cognitive function (measured by MMSE) in 12 months.
Read more about the analysis
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
2
SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years
3
SCOPE X: The COPD Case Study That Shows What AI Can Do for Enrollment
4
Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention
5




